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The insulin-like growth factor 1 receptor (IGF1R) and the insulin receptor (IR) are receptor
tyrosine kinases that are expressed in cancer cells.The results of different studies indicate
that tumor proliferation and survival is dependent on the IGF1R and IR, and that their inhi-
bition leads to reductions in proliferation and increases in cell death. Molecular targeting
therapies that have been used in solid tumors include anti-IGF1R antibodies, anti-IGF1/IGF2
antibodies, and small molecule inhibitors that suppress IGF1R and IR kinase activity. New
advances in the molecular basis of anti-IGF1R blocking antibodies reveal they are biased
agonists and promote the binding of IGF1 to integrin β3 receptors in some cancer cells.
Our recent reports indicate that pharmacological aryl hydrocarbon receptor (AHR) ligands
inhibit breast cancer cell responses to IGFs, suggesting that targeting AHR may have ben-
efit in cancers whose proliferation and survival are dependent on insulin/IGF signaling.
Novel aspects of IGF1R/IR in cancer, such as biased agonism, integrin β3 signaling, AHR,
and new therapeutic targeting strategies will be discussed.
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A SHORT HISTORY OF INSULIN/IGFs IN CANCER
IGF1R
The early evidence linking the IGF1R to cancer was the finding
that the transformation of mouse embryo fibroblasts (MEFs) by
many, but not all, tested oncogenes requires an intact Igf1r gene.
For instance, the SV40 large T antigen, H-Ras, EWS/FLI-1, and c-
Src transform wild type, but not Igf1r null, MEFs (1–4). Gα13 and
v-Src induces the transformation of wild type and Igf1r null MEFs
(4, 5). Transgenic overexpression of oncogenic Kras in the murine
mammary gland induces the formation of mammary tumors that
overexpress Igf1r (6). Such tumors resemble human basal-like
breast tumors that are resistant to therapy (6). The growth of Kras
expressing murine mammary tumors is delayed upon deletion of
the Igf1r gene from mammary tumors (6). Treating mice with the
IGF1R inhibitor picropodophyllin (PPP) suppressed the growth
of Kras expressing mammary tumors compared with vehicle (6).
PPP also inhibited the growth of MDA-MB-231 breast cancer
xenografts in mice (6). Collectively, these reports provided in vitro
and in vivo evidence that the IGF1R promotes transformation and
the progression of breast cancer.
IGF1
Liver specific Igf1 knockout mice have lower levels of circulat-
ing IGF1 (by ~75%) than wild type mice (7, 8). Lowering the
levels of circulating IGF1 in mice has been shown to inhibit the
growth of colon cancer xenografts and there is reduced incidence
of metastatic spread to the liver (7). Additionally, exogenous IGF1
increases the growth and metastasis of colon cancer in mice (7).
Similar results were observed in murine models of breast can-
cer. Specifically, breast tumors grow slower in IGF1 deficient mice
than wild type mice (9). On the other hand, transgenic overex-
pression of the human IGF1 gene in epithelial cells of the mouse
prostate induces the formation of spontaneous prostate cancer
(10). In humans, acromegaly is associated with higher incidence
rates of colorectal cancer (11). In contrast, Laron-type dwarfism
is associated with low IGF1 levels and reduced cancer risk (12).
Thus, high levels of IGF1 are associated with increased incidence
of cancer progression, while lower levels of IGF1 are associ-
ated with decreased incidence of cancer progression in mice and
humans.
Canonical signaling responses to insulin/IGFs have been
reviewed (13–16). Insulin/IGFs upon activation of their cognate
receptors induce PI3K and MAPK signaling. Increases in PI3K and
MAPK signaling in cancer cells induce proliferation and resistance
to cell death (17, 18). In addition to the canonical insulin/IGF
pathways, recent work indicates that insulin receptor substrate 1
(IRS-1) and the IGF1R translocate from the cell membrane into
the nucleus in response to IGF1 (19, 20). In the nucleus, IRS-
1 binds to the promoters of CCND1 and cMYC (21). In doing
so, IRS-1 increases the expression of CCND1 and cMYC (21).
These findings provided a mechanism by which IGF1 through
IRS-1 increases proliferation because CCND1 and cMYC induce
cell cycle advance (21). IRS-1 also binds to the promoter of ribo-
somal DNA (21). The binding of IRS-1 to the ribosomal DNA
promoter promotes ribosomal RNA synthesis, which is required
for increases in cell size (22). Ligand-induced translocation of the
IGF1R into nucleus requires the IGF1R to undergo SUMOylation
at specific lysine residues (Lys1025, Lys110, and Lys1120 in the β sub-
unit) (23). Upon entering the nucleus, SUMOylated IGF1R binds
to lymphoid enhancer-binding factor 1 (LEF1) on Wnt target gene
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promoters like CCND1 and AXIN (24). By this mechanism, the
IGF1R increases CCND1 and AXIN expression (24).
INSULIN
Mice that express a dominant negative IGF1R in skeletal muscle
(MRK mice) are insulin resistant and exhibit hyperinsulinemia
(25). MRK mice are not obese and they have mild hyperglycemia
(25). Mouse breast cancer cells that express oncogenes form
tumors when grafted into the mammary fat pad of mice. The
growth of such tumors is increased in MRK mice compared with
wild type mice (26). High levels of insulin activate the insulin
receptor (IR), but not the IGF1R, in tumors in MRK mice (27).
Mice treated with the insulin analog AspB10 develop larger mam-
mary tumors than vehicle-dosed mice (27). The IR, but not the
IGF1R, is activated in tumors in mice treated with AspB10 (27).
Western blot analysis reveals that MRK mammary tumors exhibit
higher levels of phosphorylated AKT and S6 ribosomal protein
(S6rp) than mammary tumors in control mice (28). MRK mice
dosed with pan-class I PI3K inhibitor NVP-BKM120 or the dual
PI3K/mTOR inhibitor BEZ235 had smaller tumors than MRK
mice treated with vehicle (28). PPP inhibits tumor growth in MRK
mice without inducing significant metabolic toxicity (29). This
PPP benefit was attributed to partial inhibition of the IGF1R and
IR, as discussed by the authors (29).
TCDD AND THE ARYL HYDROCARBON RECEPTOR IMPACT
IGF2 SIGNALING IN BREAST CANCER CELLS
Obesity increases the risk for several cancers including breast can-
cer (30). We (and others) have shown that adipocyte conditioned
medium (adipo-CM) stimulates the proliferation of human breast
cancer cells more than fibroblast conditioned medium (fibro-CM)
(31, 32). We identified that adipocytes secrete higher levels of
IGF2 than fibroblasts (32). Adipo-CM-stimulated breast cancer
cell proliferation was inhibited with anti-IGF2 blocking antibody
(32). 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) is a lipophilic
toxicant that inhibits estrogen signaling and disrupts interactions
between CCND1, CDK4, and RB1 (33, 34). We found that TCDD
inhibits adipo-CM- or IGF2-stimulated breast cancer cell prolif-
eration and reduces the expression of E2F1, CCND1, MYB, SRC,
JAK2, and JUND1 compared with vehicle (32). Taken together,
these data suggest that TCDD inhibits adipo-CM and IGF2 sig-
naling in breast cancer cells by downregulating the expression of
genes that are important for sustaining high rates of prolifera-
tion (32). We are currently investigating signaling mechanisms by
which TCDD regulates gene expression in human breast cancer
cells stimulated with adipokines or IGF2.
The aryl hydrocarbon receptor (AHR) is a ligand-activated
transcription factor that is best known for mediating the toxic
effects of TCDD (35). Our recent findings indicate that AHR
responds to and mediates IGF2 signaling in MCF7 breast can-
cer cells (36). We found that IGF2-treated MCF7 cells have higher
levels of AHR mRNA and protein than control cells (36). We noted
that increases in AHR protein correlated with increases in CCND1
expression in cells treated with IGF2 (36). Chromatin immunopre-
cipitation (ChIP) experiments revealed that the binding of AHR
to the CCND1 gene promoter was increased in IGF2-stimulated
MCF7 cells compared with vehicle-treated controls (36). We then
knocked down AHR with specific interfering RNA and found
that reducing AHR levels inhibited IGF2-stimulated increases in
CCND1 mRNA and protein in MCF7 cells (36). Considering that
CCND1promotes cell cycle, we asked whether knockdown of AHR
inhibits IGF2-stimulated MCF7 proliferation (36). AHR knock-
down MCF7 cells are indeed less responsive to IGF2-mediated
increases in proliferation than controls (36). Collectively, these
findings indicate that IGF2 induces signaling in MCF7 cells that
promotes the association of the AHR with the CCND1 gene
promoter, which in turn increases proliferation (36).
TUMOR RESISTANCE MECHANISMS TO IGF1R BLOCKING
THERAPY
Considering the roles of IGF/IGF1R in transformation, tumor
growth, and resistance to cell death, anti-IGF1R antibodies were
designed for cancer therapy (17, 18). Problems associated with the
anti-IGF1R antibodies included adverse endocrine effects and lim-
ited effectiveness (17, 18). The limited effectiveness of anti-IGF1R
antibodies has been attributed to tumor resistance (17, 18). Recent
work has established that IGF1R blocking antibodies have biased-
agonism activity toward the IGF1R (37). Further, blockade of the
IGF1R with antibody can promote IGF1 signaling through the
integrin β3 receptor in tumor cells (38). Biased agonism and the
binding of IGF1 to the integrin β3 receptor are novel mechanisms
of tumor resistance to anti-IGF1R antibodies that we will discuss
below.
ANTI-IGF1R ANTIBODIES ARE BIASED AGONISTS
IGF1 is a balanced IGF1R agonist that induces beta arrestin 1 (β-
arr1) and IGF1R kinase signaling pathways (39, 40) (Figure 1A).
The anti-IGF1R antibody figitumumab (CP) is a biased IGF1R
agonist because it suppresses IGF1R kinase activity, but activates
β-arr1 signaling (37) (Figure 1B). Increases in β-arr1 signal-
ing in response to CP will mediate mitogenic ERK signaling
and proteasome-mediated downregulation of the IGF1R (37)
(Figure 1B). Combining the ERK inhibitor UO126 with CP
reduces the proliferation of Ewing’s sarcoma (ES) cells more than
UO126 or CP alone (37). Thus, the results of Zheng et al. (37)
indicate that blockade of ERK by ERK inhibitors may improve the
clinical benefits of CP and other anti-IGF1R antibodies that are
biased β-arr1 agonists (37).
IGF1 BINDS TO INTEGRIN β3
Shin and colleagues in 2013 tested the effectiveness of the anti-
IGF1R antibody cixutumumab (cix) on a panel of human head
and neck squamous cell carcinoma (HNSCC) and non-small cell
lung cancer (NSCLC) cell lines (38). The authors found that the
growth of some, but not all, tested cancer cell lines was inhibited by
cix (38). Western blot analysis showed that the levels of phosphory-
lated Src, epidermal growth factor receptor (EGFR), AKT, mTOR,
and p70S6K were higher in cix-treated resistant cancer cells than
cix-sensitive cells (38). The authors recognized that IGF1 had pre-
viously been shown to bind to and activate integrin β3, but not
integrin β1, on Chinese hamster ovary cells (41). Binding assays
established that IGF1 also binds to integrin β3 on HNSCC cells
(38). Inhibiting the binding of IGF1 to the integrin β3 receptor in
cix-treated HNSCC cells blocked increases in Src signaling (38).
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FIGURE 1 | Figitumumab (CP) is a biased agonist of the IGF1R that
selectively promotes β-arrestin1 (β-arr1) signaling in cancer cells.
(A) IGF1 binding to and activation of the IGF1R stimulates the β-arr1
pathway that leads to proteasomal degradation of the IGF1R through a
ubiquitin (Ub)-mediated mechanism and ERK activation. IGF1 binding to the
IGF1R also induces IGF1R autophosphorylation and this serves to increase
the kinase pathway that promotes the phosphorylation and activation of
AKT. (B) CP binding to the IGF1R preferentially increases β-arr1 signaling,
and inhibits the IGF1R kinase pathway. By this mechanism, CP
downregulates IGF1R and AKT signaling, and increases ERK-mediated
mitogenic signaling.
Next, the authors transplanted HNSCC tumors from patients into
mice (38). Such tumors were not growth inhibited in mice dosed
with cix compared to controls (38). Knockdown of integrin β3
or inhibiting Src in primary human HNSCC rendered the tumor
xenografts sensitive to cix treatment in mice (38). Collectively,
these findings indicate that blockade of the IGF1R with cix induces
IGF1 to bind to integrin β3, which in turn induces Src signaling
that increases cancer cell growth (38).
NEW BLOCKING STRATEGIES
MEDI-573 is a human antibody that selectively targets IGF1 and
IGF2, but not insulin (42) (Figure 2). MEDI-573 affinity for
human IGF2 is higher than its affinity for human IGF1 and its
affinity for murine IGF1 is low (42). IGF2 binding to the insulin
receptor isoform A (IR-A) in cancer cells has mitogenic and tumor
promoting effects in vitro and in vivo (43, 44) (Figure 2). Because
MEDI-573 targets IGF2, it could be particularly effective in tumors
that overexpress IR-A (42). Combining an anti-IGF1R antibody
with MEDI-573 offers a better antitumor effect because of greater
inhibition of IGF1 and IGF2 signaling in cancer cells and tumor
angiogenesis is inhibited (45) (Figure 2). In addition, MEDI-573
combined with an mTOR1 inhibitor (AZD2014) inhibits sarcoma
xenografts more than MEDI-573 or mTOR1 inhibition alone (46).
MEDI-573 has been tested in phase I clinical trials in solid tumors
(47, 48). These trials showed that MEDI-573 effectively clears IGF1
and IGF2 from plasma in patients at doses below limiting toxic-
ity (47, 48). The most frequent adverse effects of MEDI-573 were
fatigue and gastrointestinal complaints (47, 48). Immunogenicity
against MEDI-573 was evaluated and none was found (47, 48).
Clinically, the tumor response to MEDI-573 was stable disease (in
~30% of patients) and no partial or complete responses occurred
(47, 48).
OSI-906 is a small molecule IGF1R/IR kinase inhibitor that sup-
presses the growth of tumor xenografts in mice (49) (Figure 2).
FIGURE 2 | Mechanism of action of MEDI-573, anti-IGF1R antibodies,
and OSI-906 in cancer cells and tumor angiogenesis. IGF2 binding to
insulin receptor subtype A (IR-A) and IGF1 binding to IGF1R in cancer cells
and tumor blood vessels promotes cancer cell survival and proliferation as
well as tumor angiogenesis. MEDI-573 is a human antibody that neutralizes
IGF2 and IGF1 and thus inhibits the cancer effects of both IGF ligands.
Anti-IGF1R antibodies inhibit IGF1 signaling through IGF1R, but not IGF2
signaling mediated by IR-A. OSI-906 is a small molecule inhibitor that
inhibits IGF1R and IR autophosphorylation and therefore IGF1 and IGF2
cancer effects.
Phase I trials have tested intermittent versus continual dosing
of OSI-906 in patients with advanced solid tumors (50, 51). In
both OSI-906 trials, hyperglycemia was an adverse effect, which
occurred more frequently in a diabetic cohort in the contin-
ual dosing study (51). Stable disease occurred in patients dosed
intermittently or continually with OSI-906 (50, 51). Further,
two patients with adrenocortical carcinoma had partial responses
to intermittent doses of OSI-906 (50). In the continuous dose
study, one patient with melanoma had a complete response to
OSI-906 (51). Overall, OSI-906 was well tolerated has antitumor
activity and warrants further study, as discussed by the authors
(50, 51).
CONCLUSION
From all apparent evidences, we propose that the insulin/IGF sys-
tem is still an effective target for cancer therapy. There is still a
need for uncovering new ways to effectively target both insulin
and IGF signaling in cancer while avoiding significant metabolic
toxicity. Part will come from the recognition of new pathways
of tumor resistance. There is also a need to identify specific bio-
markers to predict sensitivity or resistance to existing anti-IGF1R
therapies (52). Thus, collectively, insulin/IGF signaling in cancer
and its therapeutic targeting still warrants further investigation.
REFERENCES
1. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, et al. Effect of
a null mutation of the insulin-like growth factor I receptor gene on growth and
transformation of mouse embryo fibroblasts. Mol Cell Biol (1994) 14:3604–12.
2. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40
large tumor antigen is unable to transform mouse embryonic fibroblasts lack-
ing type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A (1993)
90:11217–21. doi:10.1073/pnas.90.23.11217
www.frontiersin.org February 2015 | Volume 6 | Article 12 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salisbury and Tomblin Insulin/IGFs in cancer
3. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like
growth factor-I receptor is required for EWS/FLI-1 transformation of fibrob-
lasts. J Biol Chem (1997) 272:30822–7. doi:10.1074/jbc.272.49.30822
4. Valentinis B, Morrione A, Taylor SJ, Baserga R. Insulin-like growth factor I
receptor signaling in transformation by src oncogenes. Mol Cell Biol (1997)
17:3744–54.
5. Liu JL, Blakesley VA, Gutkind JS, LeRoith D. The constitutively active mutant
Galpha13 transforms mouse fibroblast cells deficient in insulin-like growth
factor-I receptor. J Biol Chem (1997) 272:29438–41. doi:10.1074/jbc.272.47.
29438
6. Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, Efstratiadis A. Igf1r as a
therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad
Sci U S A (2009) 106:2359–64. doi:10.1073/pnas.0810221106
7. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like
growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res
(2002) 62:1030–5.
8. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth and
development in the absence of hepatic insulin-like growth factor I. Proc Natl
Acad Sci U S A (1999) 96:7324–9. doi:10.1073/pnas.96.13.7324
9. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, et al. Reduced
circulating insulin-like growth factor I levels delay the onset of chemically and
genetically induced mammary tumors. Cancer Res (2003) 63:4384–8.
10. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, et al. Dereg-
ulated expression of insulin-like growth factor 1 in prostate epithelium leads
to neoplasia in transgenic mice. Proc Natl Acad Sci U S A (2000) 97:3455–60.
doi:10.1073/pnas.97.7.3455
11. Yamamoto M, Fukuoka H, Iguchi G, Matsumoto R, Takahashi M, Nishizawa
H, et al. The prevalence and associated factors of colorectal neoplasms in
acromegaly: a single center based study. Pituitary (2014). doi:10.1007/s11102-
014-0580-y
12. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F,
Cheng CW, et al. Growth hormone receptor deficiency is associated with a major
reduction in pro-aging signaling, cancer, and diabetes in humans. Sci TranslMed
(2011) 3:70ra13. doi:10.1126/scitranslmed.3001845
13. Metz HE, Houghton AM. Insulin receptor substrate regulation of phosphoinosi-
tide 3-kinase. Clin Cancer Res (2011) 17:206–11. doi:10.1158/1078-0432.CCR-
10-0434
14. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new
players. J Mol Endocrinol (2011) 47:R1–10. doi:10.1530/JME-11-0022
15. Siddle K. Molecular basis of signaling specificity of insulin and IGF recep-
tors: neglected corners and recent advances. Front Endocrinol (2012) 3:34.
doi:10.3389/fendo.2012.00034
16. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling path-
ways: insights into insulin action. Nat Rev Mol Cell Biol (2006) 7:85–96.
doi:10.1038/nrm1837
17. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev
Cancer (2008) 8:915–28. doi:10.1038/nrc2536
18. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia:
an update. Nat Rev Cancer (2012) 12:159–69. doi:10.1038/nrc3215
19. Sun H, Tu X, Prisco M, Wu A, Casiburi I, Baserga R. Insulin-like growth factor I
receptor signaling and nuclear translocation of insulin receptor substrates 1 and
2. Mol Endocrinol (2003) 17:472–86. doi:10.1210/me.2002-0276
20. Tu X, Batta P, Innocent N, Prisco M, Casaburi I, Belletti B, et al. Nuclear
translocation of insulin receptor substrate-1 by oncogenes and Igf-I. Effect on
ribosomal RNA synthesis. J Biol Chem (2002) 277:44357–65. doi:10.1074/jbc.
M208001200
21. Wu A, Chen J, Baserga R. Nuclear insulin receptor substrate-1 activates promot-
ers of cell cycle progression genes. Oncogene (2008) 27:397–403. doi:10.1038/sj.
onc.1210636
22. Drakas R, Tu X, Baserga R. Control of cell size through phosphorylation of
upstream binding factor 1 by nuclear phosphatidylinositol 3-kinase. Proc Natl
Acad Sci U S A (2004) 101:9272–6. doi:10.1073/pnas.0403328101
23. Sehat B, Tofigh A, Lin Y, Trocme E, Liljedahl U, Lagergren J, et al. SUMOylation
mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal
(2010) 3:ra10. doi:10.1126/scisignal.2000628
24. Warsito D, Sjostrom S, Andersson S, Larsson O, Sehat B. Nuclear IGF1R is
a transcriptional co-activator of LEF1/TCF. EMBO Rep (2012) 13:244–50.
doi:10.1038/embor.2011.251
25. Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL,
et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle
causes type 2 diabetes. Genes Dev (2001) 15:1926–34. doi:10.1101/gad.908001
26. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y,
et al. Insulin-mediated acceleration of breast cancer development and progres-
sion in a nonobese model of type 2 diabetes. Cancer Res (2010) 70:741–51.
doi:10.1158/0008-5472.CAN-09-2141
27. Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z, et al.
Insulin receptor phosphorylation by endogenous insulin or the insulin analog
AspB10 promotes mammary tumor growth independent of the IGF-I receptor.
Diabetes (2013) 62:3553–60. doi:10.2337/db13-0249
28. Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, LeRoith D. Inhibiting
PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse
model of insulin resistance and hyperinsulinemia.Oncogene (2012) 31:3213–22.
doi:10.1038/onc.2011.495
29. Rostoker R, Bitton-Worms K, Caspi A, Shen-Orr Z, LeRoith D. Investigat-
ing new therapeutic strategies targeting hyperinsulinemia’s mitogenic effects
in a female mouse breast cancer model. Endocrinology (2013) 154:1701–10.
doi:10.1210/en.2012-2263
30. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence
and proposed mechanisms. Nat Rev Cancer (2004) 4:579–91. doi:10.1038/
nrc1408
31. Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C,
et al. Adipocyte-secreted factors synergistically promote mammary tumori-
genesis through induction of anti-apoptotic transcriptional programs and
proto-oncogene stabilization. Oncogene (2003) 22:6408–23. doi:10.1038/sj.onc.
1206737
32. Salisbury TB, Morris GZ, Tomblin JK, Chaudhry AR, Cook CR, Santanam
N. Aryl hydrocarbon receptor ligands inhibit igf-ii and adipokine stimu-
lated breast cancer cell proliferation. ISRN Endocrinol (2013) 2013:104850.
doi:10.1155/2013/104850
33. Barhoover MA, Hall JM, Greenlee WF, Thomas RS. Aryl hydrocarbon receptor
regulates cell cycle progression in human breast cancer cells via a functional
interaction with cyclin-dependent kinase 4. Mol Pharmacol (2010) 77:195–201.
doi:10.1124/mol.109.059675
34. Wormke M, Stoner M, Saville B, Walker K, Abdelrahim M, Burghardt R,
et al. The aryl hydrocarbon receptor mediates degradation of estrogen recep-
tor alpha through activation of proteasomes. Mol Cell Biol (2003) 23:1843–55.
doi:10.1128/MCB.23.6.1843-1855.2003
35. Denison MS, Soshilov AA, He G, DeGroot DE, Zhao B. Exactly the same
but different: promiscuity and diversity in the molecular mechanisms of
action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci (2011) 124:1–22.
doi:10.1093/toxsci/kfr218
36. Tomblin JK, Salisbury TB. Insulin like growth factor 2 regulation of aryl hydro-
carbon receptor in MCF-7 breast cancer cells. Biochem Biophys Res Commun
(2014) 443:1092–6. doi:10.1016/j.bbrc.2013.12.112
37. Zheng H,Shen H,Oprea I,Worrall C,Stefanescu R,Girnita A,et al. Beta-arrestin-
biased agonism as the central mechanism of action for insulin-like growth factor
1 receptor-targeting antibodies in Ewing’s sarcoma. Proc Natl Acad Sci U S A
(2012) 109:20620–5. doi:10.1073/pnas.1216348110
38. Shin DH, Lee HJ, Min HY, Choi SP, Lee MS, Lee JW, et al. Combating resistance
to anti-IGFR antibody by targeting the integrin beta3-Src pathway. J Natl Cancer
Inst (2013) 105:1558–70. doi:10.1093/jnci/djt263
39. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Girnita A, Lefkowitz RJ, et al. {beta}-
Arrestin is crucial for ubiquitination and down-regulation of the insulin-like
growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol
Chem (2005) 280:24412–9. doi:10.1074/jbc.M501129200
40. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A, et al.
Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation
and cell cycle progression. J Biol Chem (2007) 282:11329–38. doi:10.1074/jbc.
M611526200
41. Saegusa J,Yamaji S, Ieguchi K,Wu CY, Lam KS, Liu FT, et al. The direct binding of
insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1
signaling. J Biol Chem (2009) 284:24106–14. doi:10.1074/jbc.M109.013201
42. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones
M, et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF
signaling and tumor growth. Cancer Res (2011) 71:1029–40. doi:10.1158/0008-
5472.CAN-10-2274
Frontiers in Endocrinology | Cancer Endocrinology February 2015 | Volume 6 | Article 12 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salisbury and Tomblin Insulin/IGFs in cancer
43. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al.
Insulin receptor isoform A, a newly recognized, high-affinity insulin-like
growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999)
19:3278–88.
44. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor function-
ally enhances multistage tumor progression and conveys intrinsic resistance
to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 107:10791–8.
doi:10.1073/pnas.0914076107
45. Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, et al.
Dual targeting of the type 1 insulin-like growth factor receptor and its lig-
ands as an effective antiangiogenic strategy. Clin Cancer Res (2013) 19:2984–94.
doi:10.1158/1078-0432.CCR-12-2008
46. Zhong H, Fazenbaker C, Breen S, Chen C, Huang J, Morehouse C, et al. MEDI-
573, alone or in combination with mammalian target of rapamycin inhibitors,
targets the insulin-like growth factor pathway in sarcomas. Mol Cancer Ther
(2014) 13:2662–73. doi:10.1158/1535-7163.MCT-14-0144
47. Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, et al.
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal
antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin
Cancer Res (2014) 20:4747–57. doi:10.1158/1078-0432.CCR-14-0114
48. Iguchi H, Nishina T, Nogami N, Kozuki T, Yamagiwa Y, Yagawa K. Phase I dose-
escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-
573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced
solid tumours. Invest New Drugs (2014) 33:194–200. doi:10.1007/s10637-014-
0170-x
49. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D,
et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of
the IGF-1 receptor and insulin receptor. Future Med Chem (2009) 1:1153–71.
doi:10.4155/fmc.09.89
50. Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, et al.
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and
insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin
Cancer Res (2014) 21:1–8. doi:10.1158/1078-0432.CCR-14-0265
51. Puzanov I, Lindsay CR, Goff LW, Sosman JA, Gilbert J, Berlin J, et al. A phase
I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like
growth factor-1 and insulin receptors in patients with advanced solid tumors.
Clin Cancer Res (2014). doi:10.1158/1078-0432.CCR-14-0303
52. King H, Aleksic T, Haluska P, Macaulay VM. Can we unlock the potential of
IGF-1R inhibition in cancer therapy? Cancer Treat Rev (2014) 40:1096–105.
doi:10.1016/j.ctrv.2014.07.004
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 11 December 2014; paper pending published: 06 January 2015; accepted: 19
January 2015; published online: 02 February 2015.
Citation: Salisbury TB and Tomblin JK (2015) Insulin/insulin-like growth factors in
cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and
new blocking strategies. Front. Endocrinol. 6:12. doi: 10.3389/fendo.2015.00012
This article was submitted to Cancer Endocrinology, a section of the journal Frontiers
in Endocrinology.
Copyright © 2015 Salisbury and Tomblin. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org February 2015 | Volume 6 | Article 12 | 5
